



CONTACT:

Peter Kronenberg  
240 247-1025

(In Vienna for NAPWA)  
David Sheon  
+1 202 422-6999

FOR IMMEDIATE RELEASE

**“Research Advances from Therapeutic HIV Vaccines and Other Immune-Based Therapies” to be Showcased at NAPWA Sponsored Community Treatment Research Forum at XVIII World AIDS Conference**

(13 July 2010 Silver Spring, Maryland) The National Association of People with AIDS today announced that it is hosting a Community Treatment Research Forum, “Research Advances from Therapeutic HIV Vaccines and Other Immune-Based Therapies” to be held at the XVIII World AIDS Conference, Vienna, Austria. The event will be held in room Schubert 5, first floor, Thursday, July 22 from 9:45 to 11am.

“NAPWA has a moral responsibility to educate people with HIV and AIDS about immune-based therapy research that one day may lead to a breakthrough for people living with the virus,” said Frank Oldham Jr., President and CEO, NAPWA. “The data deserves a collective hearing. We’re extremely proud to sponsor this symposium.”

Presentations include:

*Vacc4x - a therapeutic HIV-1 vaccine based on modified peptides: Clinical trial results and update on clinical trial development*, Per Bengtsson, MD, PhD, CMO and SVP **Bionor Immuno**

*VS411 Safely Reduces Both Excessive Immune System Activation and HIV Viral Load Within 28 Days in Treatment-naïve Individuals: A Phase II HIV AV-HALT Study*, Franco Lori, MD, CEO, **ViroStatics**

*Clinical update on AGS-004: Overcoming the challenges to successful HIV immunotherapy*, Charles Nicolette, Ph.D., CSO and VP R&D, **Argos Therapeutics**

*Topically Applied DermaVir Safely Boosts HIV-specific Immune Response and Reduces Viral Load Within Six Months in Treatment-naïve Individuals: A Phase II HIV Therapeutic Vaccine Study*, Julianna Lisziewicz, PhD, CEO, **Genetic Immunity**

*TBR-652, a potent dual chemokine receptor 5/chemokine receptor 2 (CCR5/CCR2) antagonist in phase 2 development for treatment of HIV infection*, Richard Ogden PhD, Scientific Development Advisor, **Tobira Therapeutics**

- M O R E -

PAGE 2-2-2-2

*Advanced Development of Dual Acting Pyrimidinediones (IQP-0410 and IQP-0528) as Highly Potent Anti-HIV Therapeutic Drugs and Topical Microbicides*, Robert Buckheit, Ph.D., President and Chief Scientific Officer, **ImQuest Life Sciences, Inc.**

Founded in 1983 as the first network of people living with HIV/AIDS (PLWHA), the National Association of People with AIDS (NAPWA) is the oldest national AIDS organization. NAPWA is the trusted independent voice for all people living with HIV/AIDS in the United States. By engaging in the aforementioned activities, NAPWA remains a strong voice in policy, capacity building, leadership development, and social networking. NAPWA is a 501(c) 3 non-profit organization based in Silver Spring, Maryland. For more information about NAPWA, please visit [www.napwa.org](http://www.napwa.org).

###